Amplifiers

Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology

Saturday, May 30, 2020 - 3:30pm

Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19.

Key Points: 
  • Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19.
  • Tempus on-demand virtual case review system provides clinical support to physicians and care teams in a timely manner when an in-person meeting isnt possible.
  • Tempus has launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients.
  • As part of the IRB approved study, Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost.

LexaGene Places a Pre-Commercial Instrument for COVID-19 Testing in a Major Hospital Laboratory

Thursday, May 28, 2020 - 12:55pm

Given the highly contagious nature of this virus, this is a long time to wait.

Key Points: 
  • Given the highly contagious nature of this virus, this is a long time to wait.
  • Until these studies are completed and the FDA grants LexaGenes instrument EUA for COVID-19 testing, all work using LexaGene instruments is classified as Research Use Only and cannot be used for human clinical diagnostics.
  • End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press go.
  • The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Global Molecular Diagnostics Market Analysis, Trends and Forecasts with Profiles of Leading Players Including Abbott Laboratories, bioMrieux SA, Cepheid, Hologic Inc. and Thermo Fischer Scientific Inc.

Wednesday, May 27, 2020 - 3:30pm

DUBLIN, May 27, 2020 /PRNewswire/ -- The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 27, 2020 /PRNewswire/ -- The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry.
  • The PCR market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned.
  • In Japan, the PCR segment will reach a market size of US$200.2 Million by the close of the analysis period.

Global Market Trajectory & Analytics for the World Molecular Diagnostics Market: Rising Emphasis on Lab Automation to Augur Well for Market Growth - ResearchAndMarkets.com

Monday, May 25, 2020 - 5:09pm

The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry.
  • The PCR market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned.
  • In Japan, the PCR segment will reach a market size of US$200.2 Million by the close of the analysis period.

SG Blocks Completes U.S. Import Registration for the GeneFinder® COVID-19 Plus RealAmp Kit Produced by OSANG Healthcare

Friday, May 22, 2020 - 5:00pm

The GeneFinder COVID-19 Plus RealAmp Kit test is a polymerase chain reaction (PCR) SARS-CoV-2 test for COVID-19 available in the United States under the FDAs Emergency Use Authorization.

Key Points: 
  • The GeneFinder COVID-19 Plus RealAmp Kit test is a polymerase chain reaction (PCR) SARS-CoV-2 test for COVID-19 available in the United States under the FDAs Emergency Use Authorization.
  • On May 5, 2020, the Company announced the signing of a one-year, non-exclusive distributorship agreement with OHC for its GeneFinder COVID-19 Plus RealAmp Kit in the United States.
  • SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction.
  • Each project starts with GreenSteel, the structural core and shell of an SG Blocks building, and then customized to client specifications.

OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test

Friday, May 22, 2020 - 12:00pm

A product of OraSures DNA Genotek subsidiary, OMNIgeneORAL (OM-505) is an all-in-one collection kit for the detection of DNA and RNA from viruses.

Key Points: 
  • A product of OraSures DNA Genotek subsidiary, OMNIgeneORAL (OM-505) is an all-in-one collection kit for the detection of DNA and RNA from viruses.
  • Earlier this month, the Companys ORAcollectRNA kit (OR-100) was included as the collection device for anterior nares (nasal) samples EUA granted to Biocerna LLC for its PCR-based SARS-CoV-2 assay.
  • P23 Labs was able to leverage the usability studies for our OrageneDx general 510(k) clearance to reduce the time required for submitting their EUA.
  • P23 Labs combine innovation, quality, and creativity with science and information technology to emerge as a leader in molecular testing.

Abbott Releases Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Showing Strong Agreement to Lab-Based Molecular PCR Tests

Thursday, May 21, 2020 - 9:11pm

ABBOTT PARK, Ill., May 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments.

Key Points: 
  • ABBOTT PARK, Ill., May 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments.
  • The interim results are demonstrating ID NOW COVID-19 test performance is 94.7% in positive agreement (sensitivity) and 98.6% negative agreement (specificity) when compared to two different lab-based PCR reference methods.
  • "This tells us that ID NOW is performing comparable to molecular laboratory tests in detecting the virus."
  • In comparison, Roche has demonstrated 95.0% positive agreement and 98.7% negative agreement when compared to the CDC assay.

Nephron, One Medical Partner to Offer COVID-19 Testing Services

Thursday, May 21, 2020 - 3:00pm

"Part of the new normal for businesses is testing employees to make sure the workplace is safe.

Key Points: 
  • "Part of the new normal for businesses is testing employees to make sure the workplace is safe.
  • We couldn't be prouder to offer COVID-19 testing services to our employees and neighbors."
  • The Nephron CLIA-Certified lab has procured state-of-the-art technology for COVID-19 real-time PCR testing and serological antibody testing for its own employees, and for employees of neighboring businesses.
  • The lab intends to integrate with One Medical's technology platform, which is capable of supporting a comprehensive workplace reentry COVID-19 testing program.

DENSO, Global Mobility Service to Support Delivery of COVID-19 Test Kits in Indonesia

Monday, May 18, 2020 - 9:36am

Health care workers in Indonesia have relied on imported PCR test kits to trace and fight the virus, but growing demand has caused a shortage of these critical tests.

Key Points: 
  • Health care workers in Indonesia have relied on imported PCR test kits to trace and fight the virus, but growing demand has caused a shortage of these critical tests.
  • was launched to mass-produce 100 thousand PCR testing kits in Indonesia.
  • In this project, Bio Farma, an Indonesian state-run pharmaceutical company, has already started mass production of PCR test kits.
  • (2) Mobility Service Platform is a platform system that performs management, control, data analysis, etc.

ChromaCode Raises $10 Million Series C Financing From Adjuvant Capital

Tuesday, May 19, 2020 - 1:00pm

CARLSBAD, Calif., May 19, 2020 /PRNewswire/ -- ChromaCode, Inc. , a company redefining molecular testing through data science, today announced a $10 million Series C extension with an investment from Adjuvant Capital .

Key Points: 
  • CARLSBAD, Calif., May 19, 2020 /PRNewswire/ -- ChromaCode, Inc. , a company redefining molecular testing through data science, today announced a $10 million Series C extension with an investment from Adjuvant Capital .
  • The Adjuvant investment brings the company's total Series C funding to $38 million.
  • Adjuvant joins existing ChromaCode investors Northpond Ventures , New Enterprise Associates (NEA) , Domain Associates , Windham Ventures , Okapi Ventures , Moore Venture Partners and the California Institute of Technology .
  • "We're excited to work with ChromaCode and support their unique ability to offer affordable, high-throughput assays for diseases of global importance on PCR platforms.